<p><strong>This workflow confirms and quantifies 31 drugs of abuse in oral fluid (including THC) in a 4.5‑minute LC run on the </strong><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1149"><strong>Thermo Scientific Stellar mass spectrometer</strong></a><strong> using full scan + targeted MS2 (tMS2) with both HCD and CID fragmentation. With 1 µL injection and 0.1% formic acid in water/methanol mobile phases, the method supports ~13 samples/hour (up to ~320/day continuous operation) while maintaining confirmation performance via ion ratios.</strong></p><blockquote><h5><strong>Method at a glance</strong></h5><ul><li><strong>What matrix is tested?</strong> Oral fluid</li><li><strong>How many drugs?</strong> 31 drugs of abuse (panel includes THC)</li><li><strong>Run time?</strong> 4.5 minutes</li><li><strong>Throughput?</strong> ~13 samples/hour → up to ~320 samples/day (24‑hour operation)</li><li><strong>Injection volume?</strong> 1 µL</li><li><strong>Mobile phases?</strong> 0.1% formic acid in water (A) and 0.1% formic acid in methanol (B)</li><li><strong>MS acquisition?</strong> Full scan + targeted MS2 (tMS2)</li><li><strong>Fragmentation?</strong> Compound‑optimized <strong>HCD</strong> and <strong>CID</strong> in the same targeted list</li><li><strong>Confirmation strategy?</strong> Ion ratios with ±20% tolerance (typical confirmatory approach)</li></ul></blockquote><h3><strong>Why oral fluid—and why speed matters</strong></h3><p>Oral fluid is attractive for clinical and forensic toxicology because collection is simple and the matrix aligns well with high‑volume workflows (workplace/occupational, roadside, and other settings). The challenge is building a method that’s simultaneously:</p><ul><li><strong>Broad enough</strong> for today’s drug panels</li><li><strong>Sensitive enough</strong> to reach required cutoffs</li><li><strong>Fast enough</strong> to keep sample queues under control</li><li><strong>Confirmation‑ready</strong> (consistent product ions and ion ratios)</li></ul><p>A <strong>4.5‑minute</strong> method is a practical lever here: compress runtime, raise throughput, and still keep confirmation quality by optimizing MS/MS conditions per compound.</p><h3><strong>The LC method</strong></h3><p>A short, efficient separation is the foundation of the workflow:</p><ul><li><strong>UHPLC system:</strong> <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/744"><strong>Thermo Scientific Vanquish Horizon UHPLC</strong></a></li><li><strong>Column:</strong> <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/424"><strong>Thermo Scientific Accucore Biphenyl</strong></a>, 50 × 2.1 mm, 2.6 µm</li><li><strong>Mobile phase A:</strong> 0.1% formic acid in water</li><li><strong>Mobile phase B:</strong> 0.1% formic acid in methanol</li><li><strong>Injection volume:</strong> <strong>1 µL</strong></li><li><strong>Gradient runtime:</strong> <strong>4.5 minutes</strong></li></ul><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_fd3f3e8ea4.jpg" alt="Thermo Fisher Scientific: 4.5-Minute Oral Fluid LC MS Method to Detect 31 Drugs of Abuse Using Stellar MS: Figure 1: Thermo Scientific Vanquish Horizon UHPLC system." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_fd3f3e8ea4.jpg 120w," sizes="100vw" width="747" height="969"></p><h3><strong>The MS method (Full scan + targeted MS<sup>2</sup> with HCD + CID)</strong></h3><h5><strong>Acquisition approach</strong></h5><p>This method uses a “two‑layer” strategy for quantitation + confirmation:</p><ol><li><strong>Full scan</strong> (broad coverage, context, quantitative support)</li><li><strong>Targeted MS<sup>2</sup> (tMS2)</strong> (confirmation‑focused product ions, ion ratios)</li></ol><h5><strong>The key differentiator: HCD and CID in one targeted list</strong></h5><p>Instead of forcing every analyte into a single fragmentation style, the method uses both:</p><ul><li><strong>HCD</strong> (beam‑type fragmentation)</li><li><strong>CID</strong> (resonance‑type fragmentation)</li></ul><h5><strong>Why that improves method development:</strong></h5><p>Drugs of abuse span multiple chemistries. A single collision approach often works “okay” for most compounds—but one or two analytes can become persistent problems (weak qualifiers, unstable ion ratios, excess noise). Having both <strong>HCD and CID</strong> available in one method lets you optimize per compound and move faster.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_3_e4a95651a2.jpg" alt="Thermo Fisher Scientific: 4.5-Minute Oral Fluid LC MS Method to Detect 31 Drugs of Abuse Using Stellar MS: Figure 2: Thermo Scientific Stellar mass spectrometer." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_3_e4a95651a2.jpg 245w," sizes="100vw" width="645" height="377"></p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_5_88276eec6a.jpg" alt="Thermo Fisher Scientific: 4.5-Minute Oral Fluid LC MS Method to Detect 31 Drugs of Abuse Using Stellar MS: Figure 3: Full scan &amp; targeted MS2 methods, HCD and collision energies used." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_4_5_Minute_Oral_Fluid_LC_MS_Method_to_Detect_31_Drugs_of_Abuse_Using_Stellar_MS_5_88276eec6a.jpg 245w," sizes="100vw" width="768" height="279"></p><h3><strong>Why CID + HCD flexibility improves confirmation</strong></h3><p>In this workflow, <strong>HCD</strong> performed well for most compounds. But for <strong>buprenorphine</strong>, HCD produced one dominant product ion with additional low m/z noise and noticeable residual precursor. Using <strong>CID</strong> generated two high‑intensity product ions and delivered <strong>consistent ion ratios</strong> across the calibration range.</p><p>When your confirmation hinges on stable ion ratios, the ability to switch fragmentation mode (not just collision energy) is a method‑development advantage—especially for “problem analytes.”</p><h3><strong>Controllable ionization</strong></h3><p>Oral fluid methods often deal with limited sample volume and matrix effects. This workflow pairs low injection volume with ionization control using the Thermo Scientific OptaMax Plus HESI source.</p><ul><li>The OptaMax Plus HESI source supports high probe temperature capability (up to 650 °C).</li><li>In this study, a vaporizer temperature of 500 °C was used to help achieve sensitivity and improve relative peak areas across drugs of abuse.</li></ul><p><strong>Why this matters:</strong> If you’re injecting only 1 µL, ionization stability and efficiency can be the difference between “meets cutoff” and “misses at LOQ.”</p><h3><strong>Sample preparation</strong></h3><p>Oral fluid panels become more challenging when THC is included because most drugs of abuse are basic, while THC is largely neutral, and that can stress extraction chemistry.</p><p>In this workflow, oral fluid calibrators and samples were extracted using a mixed‑mode approach designed to recover THC alongside other drugs:</p><ul><li>Calibrators prepared across eight levels (broad dynamic range)</li><li>Extraction performed using mixed‑mode chemistry tips (SCX/WAX) in a dispersive SPE‑style workflow</li><li>Steps automated on a liquid handling platform to support high‑throughput consistency</li><li>Samples dried and reconstituted prior to LC‑MS analysis</li><li>Only 1 µL injected per run</li></ul><p>Even if your lab uses different automation or consumables, the method structure (fast LC + full scan + targeted MS2 with dual fragmentation) transfers well.</p><blockquote><h5><strong>Throughput math</strong></h5><ul><li><strong>4.5 minutes per injection</strong> → 60 / 4.5 = <strong>13.3 injections/hour</strong></li><li>That’s <strong>~13 samples/hour</strong> in typical phrasing</li><li>Over 24 hours: 13.3 × 24 = <strong>~320 samples/day</strong> (continuous operation)</li></ul><p>If you run a single shift, just scale accordingly (e.g., ~106/day for an 8‑hour shift, excluding QC and overhead).</p></blockquote><h3>Performance summary</h3><h5><strong>Sensitivity and linearity</strong></h5><ul><li><strong>Linearity</strong> from LOQs as low as <strong>0.25 ng/mL</strong> up to <strong>1,000 ng/mL</strong> (panel-dependent)</li><li>For THC specifically: <strong>LOQ at 1 ng/mL</strong>, with a dynamic range extending to <strong>1,000 ng/mL</strong> in this evaluation</li><li>Across the panel, LOQs were reported as <strong>lower than recommended confirmation cutoffs</strong> referenced in SAMHSA guidance and NSC Tier 1 cutoffs (study-specific outcome)</li></ul><h5><strong>Confirmation via ion ratios</strong></h5><ul><li>Ion ratios evaluated using <strong>±20% tolerance</strong> (typical confirmatory acceptance framework)</li><li>The workflow produced <strong>consistent ion ratios across calibrator levels</strong> for the full panel in this evaluation</li></ul><h5><strong>Case sample comparison (real-world relevance)</strong></h5><p>When compared against a validated triple quadrupole method for case study samples, the Stellar MS workflow:</p><ul><li>Confirmed the positive hits observed by the reference method</li><li>Reported a few additional positives for select analytes, attributed to lower LOQs</li><li>Highlighted an operational efficiency point: <strong>1 µL injection</strong> in this method versus <strong>20 µL injection</strong> in the compared method</li></ul><h3><strong>FAQ</strong></h3><div><div><ol><li><strong>How long does the LC‑MS run take for the 31‑drug oral fluid panel?</strong><br><strong>4.5 minutes per injection</strong> using a short UHPLC gradient.<br>&nbsp;</li><li><strong>How many drugs of abuse can Stellar MS detect in this workflow?</strong><br><strong>31 drugs of abuse</strong>, including <strong>THC</strong>, using full scan + targeted MS2.<br>&nbsp;</li><li><strong>What MS/MS approach is used?</strong><br>A combined strategy: <strong>full scan</strong> plus <strong>targeted MS2 (tMS2)</strong> for confirmation.<br>&nbsp;</li><li><strong>Why use both HCD and CID?</strong><br>Because some analytes fragment better—and produce more stable confirmation ions/ion ratios—under one mode versus the other. Using both increases flexibility and speeds method optimization.<br>&nbsp;</li><li><strong>What injection volume is used?</strong><br><strong>1 µL</strong> of extracted sample.<br>&nbsp;</li><li><strong>What mobile phases are used?</strong><br><strong>0.1% formic acid in water (A)</strong> and <strong>0.1% formic acid in methanol (B)</strong>.<br>&nbsp;</li><li><strong>How many samples can you run per day?</strong><br>At 4.5 minutes/injection, throughput is <strong>~13 samples/hour</strong> or <strong>up to ~320/day</strong> with continuous operation (actual throughput depends on QC and scheduling).</li></ol></div></div><h3><strong>What makes this workflow “easy” to develop on Stellar MS</strong></h3><p>Here’s the short list of features that directly reduce method‑development friction:</p><ul><li><strong>HCD or CID</strong> in one method → optimize per compound, not compromise</li><li><strong>Fast MS2 acquisition speeds</strong> (up to 140 Hz for MS2) → more data points across narrow peaks</li><li><strong>Fast polarity switching</strong> (true 5 ms) → supports mixed panels efficiently</li><li><strong>Adaptive RT</strong> (real‑time retention time window adjustment) → helps reduce reinjections when retention times drift (e.g., column aging) and supports method transfer from longer to shorter gradients</li><li><strong>OptaMax Plus HESI</strong> source control → supports sensitivity at low injection volumes</li></ul><p><i>If you’re building a fast oral fluid confirmation workflow—or updating an existing DOA panel—this 4.5‑minute method shows how Stellar MS can combine <strong>speed, confirmation-ready MS2, and fragmentation flexibility (HCD + CID)</strong> in a single targeted workflow. Reach out to learn how to adapt the targeted list, collision settings, and scheduling strategy to your lab’s cutoffs and throughput goals.</i></p><blockquote><p><strong>Visit us on&nbsp;</strong><a target="_blank" rel="noopener noreferrer" href="https://www.linkedin.com/showcase/72003132/admin/dashboard/"><strong><u>LinkedIn:</u></strong></a><strong>&nbsp;</strong>#MassSpectrometry #OralFluid #DrugsOfAbuse #MethodDevelopment #HighThroughput</p></blockquote>

4.5-Minute Oral Fluid LC MS Method to Detect 31 Drugs of Abuse Using Stellar MS

<p><strong>In our </strong><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/article/7741"><strong>previous article, we introduced the main types of detectors used in HPLC</strong></a><strong>. This time, we take a closer look at the performance characteristics of LC detectors and the specifications that should be considered when assessing whether a detector is suitable for a particular chromatographic separation. We will also compare the most common detector technologies and provide some practical guidance for choosing the right option for a specific application.</strong></p><h3><strong>What Defines an Ideal HPLC Detector?</strong></h3><p>With such a wide variety of HPLC detectors available, an obvious question arises: why is there no single detector that works for every application? The simple answer is that no detector can satisfy every analytical requirement at the same time. Nevertheless, most detector designs aim to achieve a similar set of desirable properties.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Figure_1_Detector_requirements_334605c913.webp" alt="KNAUER: Figure 1 - Detector requirements" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Figure_1_Detector_requirements_334605c913.webp 245w," sizes="100vw" width="1024" height="384"></p><h4><strong>1. High Sensitivity – Detecting Very Small Amounts</strong></h4><p>An ideal detector should be capable of measuring very low quantities of analyte, often in the nanogram or even picogram range. High sensitivity leads to lower limits of detection (LOD), can reduce sample preparation requirements, and is particularly valuable for applications such as impurity analysis or pharmacokinetic studies.</p><p>Some detector technologies, including fluorescence detection (FLD), electrochemical detection (ECD), and mass spectrometry (MS), can achieve extremely high sensitivity. However, this level of performance is often limited to specific classes of compounds.</p><h4><strong>2. Good Selectivity or Broad Applicability – Knowing What Is Being Detected</strong></h4><p>Selectivity describes how effectively a detector responds to the target analyte while minimizing interference from the sample matrix or mobile phase.</p><p>Depending on the analytical task, a detector may need to be highly selective, responding only to compounds with specific characteristics such as fluorescence or electrochemical activity. In other cases, broader applicability may be more important, allowing a wide range of compounds to be detected regardless of their molecular structure.</p><h4><strong>3. Linear Response and Broad Dynamic Range – Reliable Quantification</strong></h4><p>A good detector should provide a linear response across a sufficiently wide concentration range. This makes it possible to accurately quantify both major components and trace impurities within the same analytical method.</p><p>A broad linear range simplifies calibration and improves confidence in quantitative results. Detector response should also remain highly reproducible from one injection to another.</p><h4><strong>4. Compatibility with HPLC Conditions – Fitting the Chromatographic Method</strong></h4><p>An ideal detector should be compatible with both gradient and isocratic elution, commonly used mobile phases and additives, typical flow rates, and standard HPLC operating temperatures.</p><p>Poor compatibility may restrict method flexibility or force compromises in chromatographic performance. Some detectors provide excellent analytical performance but only under specific operating conditions, making them less suitable for certain methods.</p><h4><strong>5. Stability and Low Noise – Distinguishing Signal from Background</strong></h4><p>A stable baseline with minimal noise and drift improves the signal-to-noise ratio and overall data quality. This becomes especially important in long chromatographic runs, gradient methods, and trace-level analysis.</p><p>Lower baseline noise makes weak analyte signals easier to distinguish and directly contributes to improved detection limits.</p><h4><strong>6. Robustness, Ease of Use, and Maintenance – Supporting Routine Laboratory Work</strong></h4><p>For day-to-day use, a detector should be reliable over long sequences, straightforward to operate, and require as little maintenance as possible.</p><p>In routine laboratories, robustness and ease of operation can be just as important as analytical performance. Simple troubleshooting, low maintenance requirements, and limited consumable costs are major advantages, particularly in high-throughput environments.</p><h3><strong>The Reality: No Detector Offers Everything</strong></h3><p>Since no detector fulfils all these requirements perfectly, detector selection is inevitably a compromise between sensitivity, selectivity, universality, robustness, operating flexibility, and cost.</p><p>For this reason, multi-detector configurations are increasingly common in modern HPLC systems. Combinations such as UV + CAD or UV + MS make it possible to benefit from complementary detection principles within a single analytical workflow.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Table_1_Comparison_of_commonly_used_HPLC_detector_classes_d74817b0f0.jpg" alt="KNAUER: Table 1 - Comparison of commonly used HPLC detector classes." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Table_1_Comparison_of_commonly_used_HPLC_detector_classes_d74817b0f0.jpg 113w," sizes="100vw" width="806" height="1115"></p><h3><strong>Critical Performance Parameters of HPLC Detectors</strong></h3><h4><strong>Data Sampling Rate</strong></h4><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Figure_2_Example_for_too_less_and_too_high_data_sampling_rate_741a53edc6.webp" alt="KNAUER: Figure 2 - Example for too less and too high data sampling rate." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Figure_2_Example_for_too_less_and_too_high_data_sampling_rate_741a53edc6.webp 245w," sizes="100vw" width="1024" height="410"></p><p>The data acquisition rate, also known as the sampling rate, is one of the most important detector settings in HPLC. It describes how many data points are recorded per second and directly influences peak representation, peak shape, area precision, and baseline noise.</p><p>The higher the sampling rate, the more data points are collected. The detector processes the measurements collected over a defined time interval and averages them, and these averaged points are then used to construct the chromatogram.</p><p>At a data rate of 5 Hz, for example, five data points are acquired every second. If too few points are collected across a chromatographic peak, the resulting peak can appear jagged, poorly defined, and analytically unreliable, as illustrated on the left side of Figure 2.</p><p>At the other extreme, a setting such as 100 Hz records 100 points each second, which is often unnecessarily high for conventional HPLC. The optimum sampling rate mainly depends on chromatographic peak width.</p><p>For most standard HPLC applications, a data rate of approximately <strong>10 to 20 Hz</strong> is sufficient to generate a smooth and symmetrical Gaussian peak.</p><p>One consequence of using an excessively high acquisition rate is increased baseline noise. Statistically, the noise of the system depends on the number of data points used for averaging and decreases with the square root of the number of averaged measurements.</p><p>Selecting an appropriate sampling rate is therefore a balance between collecting enough points to describe the chromatographic peak accurately and avoiding unnecessary noise.</p><h4><strong>Noise and Drift</strong></h4><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Figure_3_Baseline_noise_and_drift_685652e641.webp" alt="KNAUER: Figure 3 - Baseline noise and drift" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Figure_3_Baseline_noise_and_drift_685652e641.webp 245w," sizes="100vw" width="1024" height="400"></p><p>What exactly is baseline noise? In simple terms, it represents the short-term fluctuations of the detector baseline over a defined period and is expressed in the units appropriate for the particular detector.</p><p>Baseline noise is typically determined from the peak-to-peak variation of the detector signal while the mobile phase passes through the system.</p><p>All HPLC detectors exhibit a certain level of noise. Potential sources include:</p><ul><li>electronic noise,</li><li>detector cell noise,</li><li>detector instability,</li><li>temperature fluctuations,</li><li>mobile-phase effects,</li><li>and other environmental or instrumental influences.</li></ul><p>Noise directly affects detector sensitivity because it determines the <strong>signal-to-noise ratio (S/N)</strong>.</p><p>A chromatographic peak is generally considered reliably detectable when its height is at least three times greater than the calculated baseline noise. This relationship is commonly used to define the <strong>limit of detection (LOD)</strong>.</p><p>The <strong>limit of quantification (LOQ)</strong> requires a stronger signal and is typically defined as approximately ten times the baseline noise.</p><p>Another important parameter affecting sensitivity is baseline drift. Drift reflects the gradual change in detector response over time and therefore provides useful information about long-term detector stability.</p><p>It is helpful to distinguish between short-term peak-to-peak noise and longer-term baseline drift over a defined time interval. Drift can be described as the average slope or change of the baseline within a specific period.</p><p>Excessive drift may reduce sensitivity and complicate chromatographic peak integration.</p><p>Short-term baseline instability can be influenced by contamination or deterioration of detector components, while long-term drift is often related to temperature stability, detector equilibration, or changes occurring within the analytical system.</p><h3><strong>How to Select the Right HPLC Detector</strong></h3><p>There is no universally “best” HPLC detector. The correct detector is simply the one that best matches the analytical task.</p><p>When selecting a detector, several practical questions can help narrow the choice.</p><h4><strong>1. Does the analyte absorb UV light or fluoresce?</strong></h4><p>If the answer is yes, optical detectors such as <strong>UV/VIS</strong> or <strong>FLD</strong> are often the simplest and most effective options.</p><p>UV/VIS detection is widely applicable to compounds containing suitable chromophores, while fluorescence detection provides particularly high sensitivity and selectivity for naturally fluorescent or derivatized analytes.</p><h4><strong>2. Does the analyte lack a chromophore?</strong></h4><p>If UV absorption is weak or absent, detectors such as <strong>RID, ELSD, or CAD</strong> may provide a more appropriate solution.</p><p>These detector types are useful for compounds such as sugars, lipids, polymers, and other analytes that are difficult to monitor by conventional UV detection.</p><h4><strong>3. Is structural information required?</strong></h4><p>If structural information is important, <strong>mass spectrometry</strong> is usually the strongest choice.</p><p>MS provides mass-to-charge information and, when tandem mass spectrometry is used, fragmentation data that can support compound identification and structural characterization.</p><h4><strong>4. Is extremely high sensitivity necessary?</strong></h4><p>For applications requiring very low detection limits, <strong>electrochemical detection</strong> or <strong>mass spectrometry</strong> may be the most suitable options.</p><p>The exact choice depends on the chemical properties of the analyte and the required degree of selectivity.</p><h4><strong>5. Are macromolecules such as proteins or polymers being investigated?</strong></h4><p>For characterization of macromolecules, <strong>MALS</strong> and <strong>viscometry</strong> can provide valuable information about molecular weight, molecular size, branching, and aggregation.</p><p>These techniques are especially powerful when combined with size-exclusion chromatography and can provide information that is not based solely on column elution behavior.</p><p>For a more detailed discussion of detector selection, see the KNAUER blog article <i>“The way you look at it – A comprehensive guide for selecting the appropriate HPLC detector.”</i></p><p>Choosing the detection technology based on analyte properties, required sensitivity, chromatographic conditions, and the type of information needed is essential for obtaining reliable and meaningful HPLC results.</p><h3><strong>Final Thoughts</strong></h3><p>Understanding the desired characteristics and key performance parameters of HPLC detectors helps explain why different detector technologies are suited to different applications.</p><p>No single detector can provide maximum sensitivity, selectivity, universality, robustness, flexibility, and low operating cost simultaneously. Recognizing these trade-offs provides a practical framework for selecting the most appropriate detector for a given chromatographic method.</p><p>Parameters such as data sampling rate, baseline noise, drift, dynamic range, and compatibility with chromatographic conditions are just as important as the underlying detection principle itself.</p><p>In the next articles of this series, we will take a closer look at the individual HPLC detection technologies, beginning with the most widely used optical detection method: <strong>UV/VIS detection</strong>.</p>

Seeing is Believing – Detection Made Easy Part 2: Detector Characteristics

<p><strong>Our Library never stops expanding. What are the most recent contributions to LabRulezLCMS Library in the week of 17th August 2026? Check out new documents from the field of liquid phase, especially HPLC and LC/MS techniques!</strong></p><blockquote><p><span style="font-size:20px;">👉 </span><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library"><span style="font-size:20px;"><strong>SEARCH THE LARGEST REPOSITORY OF DOCUMENTS ABOUT LCMS AND RELATED TECHNIQUES</strong></span></a></p></blockquote><blockquote><p><strong>👉 Need info about different analytical techniques?</strong> Peek into <a target="_blank" rel="noopener noreferrer" href="https://gcms.labrulez.com/library"><strong>LabRulezGCMS</strong></a> or <a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/library"><strong>LabRulezICPMS</strong></a> libraries.</p></blockquote><p>This week we bring you posters by <strong>Agilent Technologies / ASMS, Thermo Fisher Scientific / ASMS </strong>and<strong> Shimadzu / ASMS </strong>and application note by<strong> Waters Corporation!</strong></p><h3><strong>1. Agilent Technologies / ASMS: Quantitation of N-Nitroso Duloxetine N-Nitrosamine Drug Substance Related Impurities (NDSRI) in API and Formulation by 6475 LC/TQ</strong></h3><ul><li>Poster</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/po_drug_impurities_lc_tq_tp_402_asms_2026_en_agilent_b933b9bddf.pdf"><strong>Full PDF for download</strong></a></li></ul><p>Nitrosamine impurities are nitroso derivatives where the nitroso group is attached to an amine. The active pharmaceutical ingredient (API) derived from a class of nitrosamines are known as N-nitrosamine drugsubstance-related impurities (NDSRI). Nitrosamine impurities in APIs and drug products pose safety concerns, even in small quantities, and thus are a major concern for drug makers [1].&nbsp;</p><p>Analytical methods must be sufficiently sensitive to quantify the nitrosamine of interest at levels as low as 10% of the specification limit and, where feasible, down to ≤5% of the specification limit, for the determination of the limit of detection. LC/MS/MS is an inherently selective and highly sensitive analytical technique that is well suited for the identification and quantification of trace-level impurities at extremely low concentrations. Consequently, LC/MS/MS has been widely adopted within the pharmaceutical industry, particularly for nitrosamine analysis [2-3].&nbsp;</p><p>Therefore, manufacturers must develop and qualify a dedicated analytical method that is appropriate for the specific sample matrix and targeted NDSRIs. An LC/MS/MS method based on multiple reaction monitoring (MRM) was developed for the detection and quantification of the N-nitroso duloxetine NDSRI impurity over a concentration range of 0.5 to 40 ppb (absolute standard concentration), using an atmospheric pressure chemical ionization (APCI) source on an Agilent 6475A LC/TQ instrument.</p><h4><strong>Experimental</strong></h4><ul><li><strong>MS:</strong> <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=6475"><strong>6475 Triple Quadrupole LC/MS System</strong></a></li><li><strong>Column:</strong> <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=Poroshell+HPH+C18"><strong>Poroshell HPH C18</strong></a> (4.6*150mm, 2.7µm)</li></ul><h4><strong>Conclusions</strong></h4><ul><li>A highly sensitive and robust MRM LC/MS/MS method was developed for the quantitation of N-nitroso duloxetine in duloxetine hydrochloride API and finished formulation using the Agilent 6475A LC/TQ.&nbsp;</li><li>The optimized chromatographic conditions provided effective separation of the analyte from the API, placebo, and formulation matrices, ensuring reliable quantitation.&nbsp;</li><li>The calibration curve was linear over the concentration range of 0.5-40 ng/mL, with 1/x weighting. R and R2 values were observed for both to be greater than 0.99.&nbsp;</li><li>Recovery studies demonstrated efficient sample extraction, with recoveries ranging from 92-99% in API samples and 109-116% in pellet formulations at the LOQ, specification, and 200% specification levels.&nbsp;</li><li>The method also showed excellent reproducibility across all evaluated concentration levels, confirming its suitability for routine analysis.</li></ul><h3><strong>2. Shimadzu / ASMS: Non-Targeted Analysis of Per- and Polyfluoroalkyl Substances in Environmental Extracts by Microflow LC-QToF Coupled with Multi-spray ESI</strong></h3><ul><li>Poster</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/TP_562_Non_Targeted_Analysis_of_Per_and_Polyfluoroalkyl_Substances_in_Environmental_Extracts_by_Microflow_LC_Q_To_F_Coupled_with_Multi_spray_ESI_c2a7e1d5bf.pdf"><strong>Full PDF for download</strong></a></li></ul><p>Targeted screening methods are well established for monitoring Perand polyfluoroalkyl substances (PFAS) in environmental samples. However, PFAS comprise a large and evolving class of compounds, creating a need to screen existing, emerging, and transformation products across diverse matrices. Non-targeted Analysis (NTA) allows for the confirmation of suspected PFAS in the environment, but the sample characterization is often limited by analytical sensitivity. Microflow (0.5 – 40 µL/min) coupled with a multi-nozzle emitter enhances sensitivity by improving desolvation. When this is coupled to a high mass accuracy and resolution Quadrupole Time-ofFlight Mass Spectrometer (QToF), capable of data-dependent and independent MS/MS, PFAS characterization of unknown analytes is possible. In this study, various environmental extracts were processed and screened using NTA for PFAS compounds.</p><h4><strong>Methods</strong></h4><p>A <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=1&amp;search=Nexera+Mikros"><strong>Shimadzu Nexera Mikros LC</strong> </a>was used to introduce the sample to a Newomics DuoESI source with an M3 emitter on a <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=1&amp;search=9050"><strong>LCMS-9050 QToF MS</strong></a> (Fig. 1). A direct injection on an octadecyl column without delay column was performed. Direct injection was chosen over trapand-elute configuration to minimize selectivity bias caused by the trap column.&nbsp;</p><h4><strong>Conclusion</strong></h4><p>With the increased sensitivity of microflow LC-QToF coupled with multi-spray ESI with DIA acquisition, Insight Explore aided in NTA PFAS analysis. When paired with Insight Discovery and Profiler, a streamlined batch data processing workflow with statistical analysis was shown to effectively handle complex environmental matrices and their analyses.</p><h3><strong>3. Thermo Fisher Scientific / ASMS: Robust and sensitive quantitation of 18 steroids in human serum using Thermo Scientific TSQ Certis Triple Quadrupole mass spectrometer</strong></h3><ul><li>Poster</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/po_004707_lsms_18_steroids_tsq_certis_clinical_po004707_asms2026_na_en_244c52437b.pdf"><strong>Full PDF for download</strong></a></li></ul><p>Accurate quantification of endogenous steroids in human serum is essential for biomonitoring physiological functions such as hormone regulation, reproduction, and immune response in clinical research laboratories. Liquid chromatography–tandem mass spectrometry (LC–MS/MS) is the gold standard for steroid analysis due to its superior sensitivity, selectivity, and multiplexing capability compared to immunoassays. However, steroid measurements remain challenging because of low endogenous concentrations and complex serum matrices. Here, we describe a robust and sensitive LC–MS/MS method for the simultaneous quantification of 18 steroids in human serum using the Thermo Scientific TSQ Certis triple quadrupole mass spectrometer (Figure 1). The method leverages advanced ion source design and fast acquisition to deliver enhanced sensitivity, stability and throughput suitable for high-volume laboratory workflows.</p><h4><strong>Materials and methods</strong></h4><h5><strong>Liquid chromatograph – mass spectrometry&nbsp;</strong></h5><p>Samples were analyzed on a <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/744"><strong>Thermo Scientific Vanquish Horizon UHPLC system</strong></a> coupled to the <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2207"><strong>TSQ Certis MS</strong></a><strong> </strong>operated in selected reaction monitoring (SRM) mode. The mobile phase composition, analytical column details, LC gradient, and overlaid extracted ion chromatograms (EICs) are shown in Figure 3.&nbsp;</p><h5><strong>Data analysis&nbsp;</strong></h5><p>Data were acquired and processed using <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/77"><strong>Thermo Scientific TraceFinder software</strong></a> (v 5.2).</p><h4><strong>Conclusions&nbsp;</strong></h4><p>A sensitive and robust LC–MS/MS method was developed for simultaneous quantification of 18 steroids in human serum using the Vanquish Horizon UHPLC and TSQ Certis MS with OptaMax Plus ion source. The method demonstrated excellent linearity, accuracy, and reproducibility across a wide dynamic range. Optimization of MS conditions, particularly vaporizer temperature, significantly improved sensitivity. Overall, the workflow delivers high sensitivity, selectivity, and long-term stability, providing a reliable solution for high-throughput steroid analysis in clinical and research settings.</p><h3><strong>4. Waters Corporation: Alkaline-hydrolysis Method for PFAS in Textiles and Textiles Products by Xevo™ TQ-S micro with ACQUITY™ UPLC™ H-Class Plus System</strong></h3><ul><li>Application note</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/720009443_en_0ab4914d72.pdf"><strong>Full PDF for download</strong></a></li></ul><div><div><section><div><div><div><div><div><div><h5><strong>Benefits&nbsp;</strong></h5><ul><li>Alkaline hydrolysis method (EN 17681-1:2025) used for preparing textiles, coated textiles and textile products for PFAS analysis allowed the inclusion of side-chain fluorinated polymers&nbsp;</li><li>Extraction method provided significant advantages in handling complex textile matrices by creating clear extracts free from dispersions, settleable solids and particulates&nbsp;</li><li>Protected the high-value LC-MS/MS components from potential damage&nbsp;</li><li>The method improved analytical sensitivity, reproducibility and accuracy, enabled cost-effective and timeefficient PFAS analysis maintained high analytical quality even for challenging high-matrix samples</li></ul><p>Many PFAS are linked to health concerns because of their ability to interfere with the body’s hormone systems, acting as endocrine disruptors also, linked to other toxic effects. Since textiles come into direct and prolonged contact with the skin, there is an increased risk of human exposure—especially for babies and children.4 In addition, PFAS pose significant environmental concerns. These “forever chemicals” do not readily break down and can be released during manufacturing, washing and disposal, allowing them to enter water pathways and persist in the environment. As a result, testing for PFAS has become increasingly important in the textile industry to demonstrate supply chain transparency, build consumer trust and protect brand reputation.</p><p>Synthetic fluorinated chemicals are categorized into two main groups - non-polymeric PFAS and polymeric PFAS, known for their use as water and grease repellent, heat resistant finishes in textiles, upholstery, leather, apparel, carpet and other industrial applications such as packaging, firefighting foams, non-stick cookware, etc. (Figure 1). PFAS are fluorinated substances contain at least one fully fluorinated methyl or methylene carbon atom (without any H/Cl/Br/I atom attached to it), i.e. with a few noted exceptions, any chemical with at least a perfluorinated methyl group or a perfluorinated methylene group.2 PFAS are classified as long chain and short chain based on their perfluorinated carbon chain length. Short chain fluorinated polymers encompasses a diverse range of chemistries, categorized according to their generic chemical and repeating units structures. Few examples are: derivatives of fluorotelomers, perfluoropolyethers with varying carbon chain lengths and acrylates, epoxylates, urethane, silicones of repeated units based structures.3 Polyfluoroalkyl substances such as fluorotelomer alcohols (FTOHs) contain C–H bonds, rendering them more susceptible to degradation. The ethoxylates in fluorotelomers-methacrylate break down to FTOH whereas polymeric fluorinated urethanes, acrylates break down to PFCAs (non-polymeric and polymeric side chain fluorinated polymers). In contrast, perfluoroalkyl substances such as PFOS and PFOA are extremely persistent due to their fully fluorinated carbon chains.&nbsp;</p><p>In alkaline hydrolysis methods, methanolic aqueous sodium hydroxide is used to break down precursor PFAS such as FTOHs, branched side chain PFAS. This process releases terminal perfluorinated carboxylic acids (PFCAs), which can then be measured. However, the efficiency of hydrolysis varies among different PFAS compounds and the presence of interfering substances such as organic matter or other chemicals in the sample matrix can inhibit the cleavage and detection of these analytes.</p><h4><strong>Experimental</strong></h4><ul><li><strong>LC system:</strong> <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/198"><strong>ACQUITY UPLC H-Class Plus System</strong></a> and SMFTN fitted with PFAS kit</li><li><strong>Column(s):</strong> <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1823"><strong>XBridge™ BEH™ C18 5 µm Column</strong></a>, 4.6 x 100 mm&nbsp;</li><li><strong>MS system: </strong><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/209"><strong>Xevo TQ-S micro Mass Spectrometer</strong></a></li></ul><h4><strong>Conclusion&nbsp;</strong></h4><p>By strictly following the critical steps of the alkaline hydrolysis method using methanolic aqueous sodium hydroxide (NaOH) both freely extractable PFAS and those previously bound within side-chain fluorinated polymers such as esters linked to fluorotelomer alcohols (n:2 FTOHs, where n = 4, 6, 8, 10, 12), can be effectively extracted. This approach also safeguards the LC-MS/MS instrumentation from blockages, damage, or contamination by preventing polymer accumulation and matrix interferences.&nbsp;</p><p>The analytical method using the ACQUITY UPLC H-Class Plus System and Xevo TQ-S micro LC-MS/MS System was found to be sensitive, reproducible and accurate, enabling cost-effective and time-efficient PFAS analysis in chemically processed textiles, coated textiles and textile products whilst maintaining high analytical quality even for challenging high-matrix samples.</p></div></div></div></div></div></div></section></div></div>

News from LabRulezLCMS Library - Week 34, 2026

Article

Product

Application

Academy

Video

Poster

A unique company dedicated to serving science helping our customers drive productivity and accelerate results. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services.

Thermo Fisher Scientific

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Based in Berlin, KNAUER is a medium-sized, owner-managed company that has been serving the sciences since 1962. We develop and manufacture scientific instruments of superior quality for liquid chromatography, including: Analytical HPLC/UHPLC, Preparative HPLC, Fast protein liquid chromatography (FPLC), Multi-column chromatography/Simulated moving bed (SMB) chromatography. High pressure dosing, in-line detection systems, and osmometry are additional business areas.

KNAUER

Separation Science

Agilent Technologies

Bruker

Shimadzu Corporation

SCIEX

Waters Corporation

<h4><strong>Virtual event: Pharma conclave series 2024</strong></h4><p>SCIEX offers the platform for the experts to take the stage and drive technological progress</p><p><strong>Welcome to Pharma conclave series 2024</strong> – where our customers’ expertise meets innovation, transforming your knowledge and empowering you to revolutionize your work processes. Join us in discovering techniques that will enhance your skills to accelerate your daily operations in the development of new drugs.</p><p>From the research of new markers to the drug development moving into non and GLP bioanalysis. Confidently plan your next lab expansion with the knowledge gained from industry leaders and pioneers.</p><ul><li>May 16 <strong>Event 1: Pharma omics</strong></li><li>September 17 <strong>Event 2: Impurities</strong></li><li>October 23-24 <strong>Event 3: Pharma</strong></li></ul><p><strong>10:00 a.m.–12:00 p.m. CET</strong></p><h3><strong>Event 3: Pharma</strong></h3><p><strong>The pharma connection</strong></p><p>From discovery to QA/QC. All the process to bring a new treatment to the patients is following a path to connect the different stages until the magic happens.</p><p>Join to see how the scientists are generating the needed tricks to connect the initial though with the final formulation.</p><h3><strong>Day 1</strong></h3><h5><strong>10:00 - 10:30 - Metabolomics screening kits for use in clinical trials</strong></h5><ul><li>Heike Wiese, Nuvisan</li></ul><h5><strong>10:30 – 11:00&nbsp;- Sphingolipid biomarkers in neurodegenerative drug development</strong></h5><ul><li>Jose Carlos Gonzalez, AMSbiopharma</li></ul><h5><strong>11:00 – 11:30 - Parallel setup of a series of micro LC methods, coupled with the low-resolution mass spec (API7500) for &nbsp;TG2 inhibitors</strong></h5><ul><li>Davide Massari and Chiara Olmi, ERBC Group</li></ul><h5><strong>11:30 – 12:00&nbsp;- PFAS analysis and mass spectrometry: Beyond environmental, food and packaging. What about cosmetic and pharmaceutical products?</strong></h5><ul><li>Emiliano De Dominicis, Merieux</li></ul><blockquote><p><strong>Presenter:</strong> Bruno Manadas, PhD</p></blockquote><blockquote><p>Dr Manadas is a prominent Cell Biology researcher at CNC-UC since 2017. With expertise in biochemistry, psychology, and biotechnology, he's authored 130+ publications and led multiple projects. As head of CNC's Mass Spectrometry node and Associate Editor for Frontiers, he's contributed significantly to neuroscience and psychiatry. Bruno's research focuses on cell biology mechanisms, translational biomarker research, and MS-based approaches for studying protein oxidation. He played a pivotal role in establishing the hospital biobank and teaches at the Portuguese Catholic University.</p></blockquote><blockquote><p><strong>Presenter:</strong> Dorte Bekker-Jensen</p></blockquote><blockquote><p>Dorte is heading the Applications Development team in Proteomics Research at Evosep. She has long-term experience within proteomics and has focused on technology development by developing simple and automated workflows for high-throughput applications.</p></blockquote><blockquote><p><strong>Presenter:</strong> Stefan Ledinger</p></blockquote><blockquote><p>Stefan has 20 years of experience in the life sciences and diagnostic industries. For the last dozen years, he has been serving various functions within biocrates life sciences ag. Most recently, he has been responsible for the market development for metabolomics solutions in the pharmaceutical and biotech industries. He currently serves as Global Head of Sales. Stefan holds degrees in business administration and bioengineering, combining commercial know-how with a passion for science.</p></blockquote><blockquote><p><strong>Presenter:</strong> Markus Langsdorf</p></blockquote><blockquote><p>Markus has 14 years of experience in life sciences industries. As he joined biocrates in 2010, he worked for 11 years as application support specialist for biocrates’ metabolomics profiling solutions. 3 years ago he changed his position withing the company to his new function as product manager. Markus studied chemistry and graduated with a PhD in Analytical Chemistry.</p></blockquote>

Pharma conclave series 2024: Pharma (Day1)

From discovery to QA/QC. The process to bring a new treatment to the patients.

<h4><strong>Virtual event: Pharma conclave series 2024</strong></h4><p>SCIEX offers the platform for the experts to take the stage and drive technological progress</p><p><strong>Welcome to Pharma conclave series 2024</strong> – where our customers’ expertise meets innovation, transforming your knowledge and empowering you to revolutionize your work processes. Join us in discovering techniques that will enhance your skills to accelerate your daily operations in the development of new drugs.</p><p>From the research of new markers to the drug development moving into non and GLP bioanalysis. Confidently plan your next lab expansion with the knowledge gained from industry leaders and pioneers.</p><ul><li>May 16 <strong>Event 1: Pharma omics</strong></li><li>September 17 <strong>Event 2: Impurities</strong></li><li>October 23-24 <strong>Event 3: Pharma</strong></li></ul><p><strong>10:00 a.m.–12:00 p.m. CET</strong></p><h3><strong>Event 3: Pharma</strong></h3><p><strong>The pharma connection</strong></p><p>From discovery to QA/QC. All the process to bring a new treatment to the patients is following a path to connect the different stages until the magic happens.</p><p>Join to see how the scientists are generating the needed tricks to connect the initial though with the final formulation.</p><h3><strong>Day 2</strong></h3><h5><strong>10:00 - 10:30&nbsp;- Metabolomics: From target engagement to metabolic phenotyping. Applications in drug discovery</strong></h5><ul><li>Filippos Michopoulos, Astrazeneca</li></ul><h5><strong>10:30 - 11:00&nbsp;- Development of an LC-MS Method to Quantify Endogenous Urea in Mouse Plasma and BAL.</strong></h5><ul><li>Benjamin Smith, Cyprotex</li></ul><h5><strong>11:00 - 11:30&nbsp;- Optimization of extraction &amp; LC-MS conditions for the bioanalysis of antibody drug conjugates with diverse chemistries</strong></h5><ul><li>John Perkins, KCAS</li></ul><h5><strong>11:30 - 12:00&nbsp;- Preparation of rodent whole blood and plasma microsamples for LC-MS/MS bioanalysis in toxicology studies</strong></h5><ul><li>Birgitte Støvring, Scantox</li></ul><blockquote><p><strong>Presenter:</strong> Bruno Manadas, PhD</p></blockquote><blockquote><p>Dr Manadas is a prominent Cell Biology researcher at CNC-UC since 2017. With expertise in biochemistry, psychology, and biotechnology, he's authored 130+ publications and led multiple projects. As head of CNC's Mass Spectrometry node and Associate Editor for Frontiers, he's contributed significantly to neuroscience and psychiatry. Bruno's research focuses on cell biology mechanisms, translational biomarker research, and MS-based approaches for studying protein oxidation. He played a pivotal role in establishing the hospital biobank and teaches at the Portuguese Catholic University.</p></blockquote><blockquote><p><strong>Presenter:</strong> Dorte Bekker-Jensen</p></blockquote><blockquote><p>Dorte is heading the Applications Development team in Proteomics Research at Evosep. She has long-term experience within proteomics and has focused on technology development by developing simple and automated workflows for high-throughput applications.</p></blockquote><blockquote><p><strong>Presenter:</strong> Stefan Ledinger</p></blockquote><blockquote><p>Stefan has 20 years of experience in the life sciences and diagnostic industries. For the last dozen years, he has been serving various functions within biocrates life sciences ag. Most recently, he has been responsible for the market development for metabolomics solutions in the pharmaceutical and biotech industries. He currently serves as Global Head of Sales. Stefan holds degrees in business administration and bioengineering, combining commercial know-how with a passion for science.</p></blockquote><blockquote><p><strong>Presenter:</strong> Markus Langsdorf</p></blockquote><blockquote><p>Markus has 14 years of experience in life sciences industries. As he joined biocrates in 2010, he worked for 11 years as application support specialist for biocrates’ metabolomics profiling solutions. 3 years ago he changed his position withing the company to his new function as product manager. Markus studied chemistry and graduated with a PhD in Analytical Chemistry.</p></blockquote>

Pharma conclave series 2024: Pharma (Day 2)

<p><strong>This webinar will guide you through optimizing your Q-TOF for superior data quality by selecting the most suitable tune mode for your samples.</strong></p><p>You will learn about the different optimisation workflows available within MassHunter Acquisition, including how to optimise Multiple Reaction Monitoring (MRM) methods for new compounds. We will also review key tools for creating and editing worklists, and discuss the benefits of Intelligent Reflex tools, demonstrating how they can be effectively implemented in your workflows.</p><p>This webinar is designed to enhance your understanding and application of MassHunter Acquisition, ensuring you can achieve optimal performance in your analytical processes.</p><blockquote><p><strong>Presenter:</strong> Day Powell (Field Application Specialist, Agilent Technologies)</p><p>Day has worked for Agilent as an Environmental Application Specialist for over a year, before this he worked for United Utilities (UU) as a Technical Specialist responsible for developing new methodologies for both LC/MS and GC/MS applications. Day has worked with PFAS for several years and helped UU to UKAS accredit a novel method for 47 PFAS in drinking water using direct injection to address the latest DWI regulations.<br><br><strong>Presenter:</strong> Jonathan Spencer (Application Specialist, Agilent Technologies)</p><p>Jonathan studied BSc Natural Sciences at the University of Nottingham and later went on to Sheffield Hallam University to study a MSc in Forensic Science.</p><p>Following graduation, he spent 2 years as a Confirmatory Analyst in an anti-doping and forensic toxicology lab, before joining Agilent as an LC/MS Applications Scientist. At Agilent, he focuses on small molecule applications using LC/TQ and LC/Q-TOF in fields of like food, forensic and environmental analysis.</p></blockquote>

Agilent Technologies: MassHunter Masterclass Months

MassHunter Acquisition for LC/TQ and MRM Method Optimisation

This session will provide a comprehensive overview of the various aspects of MassHunter Acquisition for Liquid Chromatography/Triple Quadrupole (LC/TQ) systems.

<p><strong>Join us for an enlightening Digital Classrooms session focused on the pivotal advancements in mass spectrometry (MS) technology and its applications in personalized health monitoring, early disease detection, and critical care management.</strong></p><p>This session, led by esteemed experts Dr. Naatasha Isahak and Dr. Abhik Banerjee, Zonal Technical Chief of Apollo Diagnostics' East Zone, will uncover how MS is transforming modern healthcare.</p><p>Explore how MS technology facilitates the quantification of vitamins, hormones, metabolites, and proteins, providing insights into metabolic health, nutritional status, and organ function. Additionally, through real-world case studies, learn how MS is utilized for rapid diagnosis and therapeutic monitoring in acute conditions, such as sepsis and organ failure.</p><p>Don’t miss this opportunity to understand the technical aspects of MS-based assays, as well as practical considerations for integrating these tools into clinical workflows for enhanced patient outcomes. Whether you are involved in clinical diagnostics or health management, join us to discover the expanding influence of mass spectrometry in today’s healthcare landscape.</p><h5><strong>Learning Objectives:</strong></h5><ul><li><strong>Delve into the latest advancements in MS technology and its applications in personalized health monitoring, early disease detection, and critical care management.</strong></li><li><strong>Discover how MS quantifies biomarkers like vitamins, hormones, metabolites, and proteins, and its role in assessing metabolic health, nutritional status, and organ function.</strong></li><li><strong>Gain practical insights into seamlessly integrating MS-based assays into clinical workflows, with real-world case studies demonstrating its effectiveness in rapid diagnosis and therapeutic monitoring of acute conditions like sepsis and organ failure.</strong></li><li><strong>Explore a concise overview of Shimadzu's innovative solutions tailored for wellness diagnostics and critical care applications.</strong></li></ul><blockquote><p><strong>Presenter:</strong> Dr. Abhik Banerjee (Zonal Technical Chief, East Zone, Apollo Diagnostics)</p><p>Dr. Abhik Banerjee is a highly accomplished pathologist with over 11 years of post-MD pathology experience and more than a decade as a Consultant Pathologist. He currently serves as the Zonal Technical Chief for East Zone at Apollo Diagnostics, overseeing the operations of around 30 laboratories in East India. A specialist in laboratory medicine, pathology, and quality control, Dr. Banerjee has spearheaded the establishment of the first LC-MS/MS (Tandem mass spectrometry) setup in Eastern India at Suraksha Diagnostics, Kolkata. He has held leadership roles such as Lab Director and Chief of Quality at Suraksha Diagnostics' COVID-19 Cell, and was the Nodal Officer for the only CAP-accredited medical laboratory in East India. He has contributed to the field with publications in national journals and received the Dx Leadership Award in 2019. Additionally, Dr. Banerjee is a certified lead assessor for CAP audits, has extensive experience with NABL and ISO 15189 audits, and has been an active speaker and reviewer for medical journals.</p><p><strong>Presenter:</strong> Naatasha Isahak (Market Specialist (Clinical and Forensics), Shimadzu (Asia Pacific) Pte Ltd)</p><p>Naatasha Isahak is a Product Specialist for MALDI and Life Sciences Products from Shimadzu Asia Pacific Pte Ltd. She has received her PhD from the University of Sydney (Chemistry) working on surface initiated polymerisation on silica nanoparticles using RAFT polymerisation and bioorthogonal conjugation of peptides using Native Chemical Ligation. She then spent 5 years working on developing platforms for stem cells and organoids characterization that included working with microfluidic devices and helical polymers. Naatasha joined Shimadzu in 2022 to expand her experiences to MALDI characterization on materials and biological samples.</p></blockquote>

Shimadzu: Wellness Diagnostics And Critical Care

Wellness Diagnostics And Critical Care

We will uncover how MS is transforming modern healthcare.

<div><div><p><strong>Therapeutic synthetic oligonucleotides represent unique analytical challenges in late-stage development. To meet the stringent regulatory requirements, highly specific and sensitive methods such as liquid chromatography-mass spectrometry (LC/MS) must be used. However, neither chromatography nor mass spectrometry data systems have the capabilities, both in function and in data integrity, for the typical QC analyst end user to run a highly complex method such as purity, assay, and impurity profiling for therapeutic oligos such as anti-sense oligonucleotides.</strong></p><p>In this presentation, we present a paradigm shift in software with Oligo Analysis Accelerator for OpenLab CDS. This application streamlines the analytical workflow by using a fit-for-purpose user interface while leveraging existing data integrity and compliance architecture within OpenLab CDS.</p><h4>By attending this webinar, you will:</h4><ul><li><strong>Understand the fundamentals of ion-pair reversed-phase LC/MS for oligonucleotides</strong></li><li><strong>Discover how a single quadrupole detector is used for impurity profiling of anti-sense oligonucleotides</strong></li><li><strong>Learn how fit-for-purpose software for LC/MS analysis in QC lot release can save time and enhance quality</strong></li></ul><h5>Who should attend</h5><ul><li>Analytical chemists interested in cutting-edge software for large molecule late-stage development</li><li>Analytical research and development labs interested in developing robust methods for single-stranded oligo therapeutics</li><li>Process scientists who rely on in-process control purity results to optimize synthesis and purification for oligos</li><li>Quality assurance and quality control personnel supporting oligo testing labs</li></ul><blockquote><p><strong>Presenter:</strong> Brian Rivera (Software Product Manager, Agilent Technologies)</p><p>Brian Rivera is a software product manager at Agilent Technologies with 20 years of experience in HPLC analysis of large molecules.</p></blockquote></div></div>

Separation Sciences: Boost Efficiency in Oligonucleotide QC with Software Designed for the Job

Boost Efficiency in Oligonucleotide QC with Software Designed for the Job

In this presentation, we present a paradigm shift in software with Oligo Analysis Accelerator for OpenLab CDS.

Oligonucleotide QC with Software Designed for the Job

<p><strong>In this webinar, Dr Stuart Best, Deputy Director, Drug Metabolism and Pharmacokinetics (DMPK), Sygnature Ltd, will provide an overview of analytical approaches in Discovery Bioanalysis CNS measurement, to deliver more information from lower sample volume and align with the 3R principles.</strong></p><p><span name="summary">Drug discovery programs that target the Central Nervous System require bioanalytical measurement of test compounds and neurotransmitter concentrations to establish a pharmacokinetic-pharmacodynamic (PK-PD) relationship. Bioanalytical assessment of unbound compounds in blood, brain tissue, and cerebrospinal fluid describes its distribution for the systemic circulation into the CNS. The inherently high sensitivity and specificity of LC-Triple Quadrupole Mass Spectrometry enables low level detection in small sample volumes, allowing serial sampling from single animals, reducing animal use and inter-animal variability, supporting the 3Rs principles (replacement, reduction, refinement)</span></p><p><span name="summary">The bioanalysis of neurotransmitters such acetylcholine and monoamines, is challenging due to low molecular weight, high polarity, instability, and low endogenous concentrations. At Sygnature, the </span><i><span name="summary">in vivo</span></i><span name="summary"> Pharmacology team employ microdialysis to permit assessment of neurotransmitter changes in specific brain regions. The low endogenous concentrations in brain regions and collection through dialysis probe into artificial CSF lowers further quantitation limits for neurotransmitter detection and lead to the requirements for highly sensitive and specific analytical approaches.</span></p><p><span name="summary">This presentation will describe the above approached to CNS measurement and how LC-Triple Quadrupole Mass Spectrometry enables Sygnature scientists to align to the 3R principles and maximize data output from small samples and relate test compound concentrations to neurotransmitter changes. Truly, achieving on the concept of ‘More from Less’ Stuart will also present further refinement models for assessing test compound impact on acetylcholine and enabling more physiologically relevant measurements.</span></p><h4><span name="summary"><strong>Key Learning Objectives:</strong></span></h4><ul><li><span name="summary"><strong fr-original-style="">Understand the challenges as CNS measurements of test compounds and neurotransmitter concentrations to establish PK-PD relationships</strong></span></li><li><span name="summary"><strong fr-original-style="">Explore the complexities of neurotransmitter bioanalysis in discovery DMPK due to low concentrations and instability</strong></span></li><li><span name="summary"><strong fr-original-style="">Learn the roles of LC-Triple Quadrupole Mass Spectrometry enabling sensitive detection in small samples and alignment to the 3Rs (replacement, reduction, refinement) principles</strong></span></li></ul><div><blockquote><p><strong>Presenter:</strong> Dr Stuart Best (Deputy Director, DMPK, Sygnature Ltd)</p><p><span>Dr Best's expertise spans regulated and discovery bioanalysis and discovery DMPK, from supporting DMPK screening (solubility, log D, metabolic stability, permeability, plasma protein binding, etc) through in vivo assessment of compounds to more detailed profiling to support candidate nomination and human dose prediction, including the assessment of potential risk from drug-drug interactions.</span></p><p><span>During his time in the industry Dr Best has expanded the utilisation of mass spectrometry (specifically triple quadrupole LC-MS/MS) to help solve drug discovery project challenges with a strong focus on maximizing data capture from in vivo samples, refining experimental designs to permit better PD endpoints and expanding LC-MS/MS support for biological screening assays, where a mass spectrometry end-point is required, for the measurement of more challenging endogenous analytes.</span></p></blockquote></div>

More from less: LC-MS/MS an Enabling Technology to Maximize Bioanalytical Data Collection from Small Sample Volumes

An overview of analytical approaches in Discovery Bioanalysis CNS measurement, to deliver more information from lower sample volume.

LC-MS/MS to Maximize Bioanalytical Data Collection

<div><div><div><p><strong>MALDI MS is ideally suited to increase productivity with rapid automated measurements. They provide near instant mass verification and information about impurities and degradants, which is valuable in quality control, assay optimization, and verification of substrates. Learn how the novel neofleX™ MALDI-TOF/TOF system&nbsp;enhances these workflows.</strong></p></div></div></div><div><div><div><h5><strong>Key Learning Objectives:</strong></h5><ul><li><strong>Overview of neofleX™ technology and its benefits to life sciences applications</strong></li><li><strong>Rapid automated analysis of a wide range of analytes including oligonucleotides and peptides</strong></li><li><strong>Software solutions for batch mode post-processing of automated runs</strong></li></ul></div></div></div><div><div><div><h5><strong>Who Should Attend:</strong></h5><ul><li>Characterization team leaders in biopharma companies and CROs</li><li>Mass spectrometry core lab managers</li><li>Anyone who is interested in rapid automated MS analysis</li><li>Researchers who would like to learn about the latest MALDI-TOF/TOF technology</li><li>Anyone who is interested in oligonucleotide and peptide analysis</li></ul><div><div><div><div><blockquote><div><p><strong>Presenter:</strong> Sergei Dikler, Ph.D. (Senior Market Manager, MALDI Technologies, Bruker Scientific LLC, Billerica, MA, USA)</p><p>Sergei Dikler, Ph.D., is a Senior Market Manager focused on promoting MALDI technologies. Dr. Dikler received his Ph.D. degree at Texas A&amp;M University. He is an expert in MALDI application development and high-throughput MS</p><p><strong>Presenter:</strong> Sinduri Vuppala, Ph.D. (Field Applications Specialist, Bruker Scientific LLC, Billerica, MA, USA)</p><p>Sinduri Vuppala, Ph.D., is a Field Applications Specialist for non-imaging MALDI applications at Bruker. Dr. Vuppala received her Ph.D., in Analytical Chemistry at the University of South Florida with focus on method development involving MALDI and CCS technologies.</p></div></blockquote></div></div></div></div></div></div></div>

Bruker: Rapid automated analysis using the novel neofleX™ platform

Rapid automated analysis using the novel neofleX™ platform

MALDI MS is ideally suited to increase productivity with rapid automated measurements. 

<p id="isPasted"><strong>Biotherapeutics offer targeted therapies for treating a wide range of diseases with greater specificity and efficacy. However, unlike traditional small-molecule drugs, biotherapeutics are typically larger and more complex, requiring advanced techniques for their production, purification, and characterization.</strong></p><p>Therapeutic proteins, first introduced many years ago, have continually advanced in complexity. Since the introduction of monoclonal antibodies, we now have antibody drug conjugates, bispecific antibodies, fragments and fusion proteins, all of which are in various stages of development.&nbsp;</p><p>To keep pace with biotherapeutics advances, analytical techniques must also advance.&nbsp;</p><h5><strong>In this webinar, we will present chromatography findings on:</strong></h5><ul><li><strong>New workflows for intact and peptide mapping characterization of proteins</strong></li><li><strong>Advanced column chemistries for charge variant analysis with pH and salt gradients&nbsp;</strong></li><li><strong>Rapid desalting SEC column for high throughput analysis, ADC analysis with HIC and reversed phase chemistries</strong></li><li><strong>New digestion workflows coupled to a new peptide mapping column for sequence verification and post translation modification analysis</strong></li></ul><p>This live webinar will be an excellent opportunity to boost your R&amp;D capabilities and strengthen your QC analytical methods for the characterization of biotherapeutics and gene therapies. Dr. Ken Cook will be presenting and answering your questions live.</p><p>With over 20 years of innovation, Thermo Fisher Scientific is a leader in biomolecule separation and characterization, supported by a wealth of published research.</p><p id="isPasted"><strong fr-original-style="">Who should attend?&nbsp;</strong></p><ul><li><strong fr-original-style="">Pharmaceutical and Biotech Researchers</strong>: Researchers involved in the development and characterization of biotherapeutics and gene therapies, including those working with therapeutic proteins.</li><li><strong fr-original-style="">Quality Control (QC) Analysts</strong>: Analysts responsible for ensuring the quality and consistency of biotherapeutic products, who will benefit from advanced methods in characterization and validation.</li><li>&nbsp;<strong fr-original-style="">R&amp;D Managers</strong>: Managers who oversee research and development teams working with biotherapeutics, looking to enhance their workflows and methodologies.</li></ul><blockquote><p><strong>Presenter:</strong> Dr. Ken Cook (Application Scientists Manager, Thermo Fisher Scientific)</p><p>Dr. Ken Cook began his career in academia as a Biochemistry lecturer focused on protein chemistry and metabolism. With over 30 years of industry experience at Dionex, and later Thermo Fisher Scientific, his vast knowledge supporting and developing solutions within chromatography has established him as a bio-separations expert.</p><p>Currently, Dr. Cook focuses on supporting and developing solutions for bio-pharmaceutical applications, particularly in the characterization of protein and oligonucleotide-based biotherapeutics. His work involves ongoing collaborations with both the biopharmaceutical industry and academic institutions.</p><p>His expertise includes peptide mapping using LC/HRMS, charged variant analysis with novel MS coupling, glycan analysis, aggregate analysis, and on-line process monitoring. He also has a growing interest and notable success in gene therapy characterization.</p><p>Given his immense experience, it is an honour to have Dr Cook share his knowledge.</p></blockquote>

Thermo Fisher Scientific: Innovations in Protein Characterization

Innovations in Protein Characterization

Boost your R&D capabilities and strengthen your QC analytical methods for the characterization of biotherapeutics and gene therapies.

<p><strong>Are you ready to take your LC-TQ troubleshooting skills to the next level?</strong></p><p><strong>Whether you’re a seasoned expert or just starting out, this session is packed with valuable insights and practical tips to help you maintain and optimize your system’s performance.</strong></p><h5><strong>What to Expect:</strong></h5><p>Unlock the Secrets of LC-TQ: Get a first introduction to troubleshooting and understand why it’s crucial for maintaining optimal performance.</p><ul><li><strong>Tackle Common Challenges:</strong> Learn how to identify and resolve issues like contamination, ion suppression, and clogged nebulizers.</li><li><strong>Preventive Maintenance Tips:</strong> Discover best practices for keeping your system in top shape, including the importance of regular check tunes and effective issue reporting.</li><li>Get useful resources to deepen your knowledge about LC-TQ troubleshooting and guides on where to start</li></ul><p>Come with any questions you might have about troubleshooting your LC/MS Triple Quadrupole system and submit them for the Q&amp;A session.</p><p>We look forward to welcoming you at this webinar!&nbsp;</p><p><strong>Presenter:</strong> Srinivasa Chakravarthy (Field System Specialist &amp; Certified Instructor (Single and Triple Quad LC/MS), Agilent Technologies)</p>

Agilent Technologies: Troubleshoot Your Misbehaving Triple Quadrupole LC/MS

Troubleshoot Your Misbehaving Triple Quadrupole LC/MS

Are you ready to take your LC-TQ troubleshooting skills to the next level?

<div><div><div><p><strong>Alithea Biotechnology was founded in 2019 by Fanny Giannou and Tim Fugmann to support Biopharma globally on the development of innovative therapies targeting HLA-presented peptides. Alithea has a significant track record in the absolute quantification of HLA peptides, off-target toxicity predictions and target discovery.</strong></p><p>In addition, HLA-Compass is Alithea's cloud-accessible HLA peptide database featuring the measurement of a total of 1.4 Million HLA peptides in 4160 healthy tissue, tumor tissue and cancer cell line samples for target validation and off-target toxicity prediction.</p><h5><strong>Why to join this webinar:</strong></h5><ul><li><strong>The timsTOF Ultra can lead to high quality immunopeptidomes from limited sample</strong></li><li><strong>Extensive HLA databases can significantly speed up the T-Cell-Receptor therapy development process</strong></li><li><strong>The time is ripe to bring immunopeptidomics into clinical routine</strong></li></ul><blockquote><p><strong>Presenter:</strong> Tim Fugmann, Ph.D. (Chief Scientific Officer and Co-Founder, Alithea Biotechnology GmbH, Berlin, Germany)</p><p>Tim Fugmann got his Ph.D. from ETH Zurich, on mass-spectrometric discovery of antibody targets and disease biomarkers. Later, he was leading the target discovery efforts at Philochem, before moving to the Max-Delbrueck-Centrum for Molecular Medicine in Berlin. He was later appointed professor for MS-based proteomics at JLU Giessen. In 2019 he co-founded Alithea Bio UG, which is focusing on immunopeptidomics, a topic which Tim Fugmann studied since 2012.</p></blockquote></div></div></div>

Bruker: Unlocking the full potential of immunopeptidomics with the timsTOF Ultra

Unlocking the full potential of immunopeptidomics with the timsTOF Ultra

Alithea has a significant track record in the absolute quantification of HLA peptides, off-target toxicity predictions and target discovery.

LCMS webinars focusing on LC/MS/MS - page 42